Critical Care & Emergencies (all articles)
CDC Report: Transmission of pan-resistant Candida auris in health care facilities.
28 Jul, 2021 | 09:59h | UTCCommentaries:
CDC reports two outbreaks of pan-resistant Candida auris – CIDRAP
U.S. sees first cases of dangerous fungus resistant to all drugs in untreated people – STAT
Related:
Case reports: Multidrug-resistant Candida auris infections in critically ill Covid-19 patients
Candida auris: A Review of Recommendations for Detection and Control in Healthcare Settings
Global Epidemiology of Emerging Candida Auris (reviews and commentaries on the subject)
The superbug Candida auris is giving rise to warnings — and big questions – STAT
Candida Auris – “A Mysterious Infection, Spanning the Globe in a Climate of Secrecy” (reviews and commentaries on the subject)
Commentaries on Twitter
⛔Breaking⛔
For the 1st time ever, CDC researchers reported 5 cases of people carrying pan-resistant
Candida.auris "3 Washington,D.C.2:Texas" resistant to all classes of antifungal drugs none had been treated with antifungal drugs prior to the diagnosishttps://t.co/uzj6wGI6Ps— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) July 22, 2021
Candida auris is a fungus that spreads easily and can cause dangerous infections. New evidence is emerging that cases of C. auris resistant to all classes of antifungal drugs are spreading in health care settings. Read the report: https://t.co/olhWJZM4r5. #Cauris pic.twitter.com/1MgMSLsKyc
— CDC (@CDCgov) July 23, 2021
M-A of randomized trials: Conservative oxygen therapy for critically ill patients.
28 Jul, 2021 | 09:41h | UTC
NICE Guideline | Clostridioides difficile infection: antimicrobial prescribing.
27 Jul, 2021 | 03:34h | UTCInfographic: Clostridioides difficile infection: antimicrobial prescribing
Related:
Review | My Treatment Approach to Clostridioides difficile Infection.
Review: Managing hyperglycemia in inpatients.
27 Jul, 2021 | 03:21h | UTCManaging hyperglycaemia in inpatients – Clinical Medicine Journal
[Preprint] RCT: In patients with COVID-19 and severe hypoxia, dexamethasone 12 mg did NOT result in statistically significant improved outcomes compared to dexamethasone 6 mg – “Mortality at 28 days was 27.1% and 32.3% in patients assigned to 12 mg and 6 mg, respectively (adjusted relative risk 0.86, 99% CI, 0.68-1.08)”.
26 Jul, 2021 | 03:01h | UTC
Large cohort study finds one in two hospitalized COVID-19 patients develop a complication.
26 Jul, 2021 | 03:00h | UTCCommentaries:
In-hospital complications associated with COVID-19 – The Lancet
CV Complications Common in Hospitalized COVID-19 Patients – TCTMD
Almost Half of Patients Admitted With COVID-19 Have Complications – HealthDay
Commentary on Twitter (thread – click for more)
NEW—An observational study of >70,000 people in the UK hospitalised with severe #COVID19 finds 1 in 2 developed at least one health complication. Authors warn of significant challenges for individuals and health & social care in the coming years.
🔗 https://t.co/CTLsPJcGZ7 pic.twitter.com/voMEDVXO9U
— The Lancet (@TheLancet) July 15, 2021
Study: Lateral flow antigen testing can rapidly and accurately detect early COVID-19 among patients presenting with flu-like illness and can be a plausible alternative to RT-PCR.
26 Jul, 2021 | 02:56h | UTCNews release: Lateral flow tests are 95% effective at detecting Covid-19 when used at the onset of symptoms – University of Oxford
Related:
Rapid point-of-care tests for diagnosing COVID-19 infection: the latest Cochrane evidence
Commentary on Twitter (thread – click for more)
Comparing the diagnostic accuracy of point-of-care lateral flow antigen testing for SARS-CoV-2 with RT-PCR in primary care (REAP-2)
Thread on today's @EDGEclinical paper, with some recommendations at the end for how we can improve UK testing. 🧵
— The Sharing Scientist (@ScienceShared) July 14, 2021
Case report: Kawasaki-like multisystem inflammatory syndrome associated with SARS-CoV-2 infection in an adult.
26 Jul, 2021 | 02:52h | UTCRelated:
Case report: Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection.
Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection
Case Reports: 2 Adults with Kawasaki-like Multisystem Inflammatory Syndrome Associated with COVID-19
Position paper: Advancing precision medicine for acute respiratory distress syndrome.
26 Jul, 2021 | 02:28h | UTCRelated:
Review: Personalized mechanical ventilation in acute respiratory distress syndrome.
Seminar | Acute respiratory distress syndrome.
ARDS: Contemporary management and novel approaches during COVID-19
Editorial | Antibiotic overuse: managing uncertainty and mitigating against overtreatment.
26 Jul, 2021 | 02:16h | UTCAntibiotic overuse: managing uncertainty and mitigating against overtreatment – BMJ Quality & Safety
Commentary on Twitter
Our editorial in @BMJ_Qual_Saf discusses uncertainty and antibiotic overuse, and identifies 4 strategies to address the tendency to prescribe 'just in case'. @EM_Krockow https://t.co/kvIG5uxxOL pic.twitter.com/eTIuqGOj1o
— Prof Carolyn Tarrant (@carolynctarrant) July 21, 2021
Review: Timing and completeness of revascularization in acute coronary syndromes.
26 Jul, 2021 | 02:21h | UTCTiming and completeness of revascularisation in acute coronary syndromes – Heart
Commentary on Twitter
Education: Timing and completeness of revascularisation in acute coronary syndromes https://t.co/VBQ76c3545 pic.twitter.com/tpNaZfhrxI
— Heart_BMJ (@Heart_BMJ) July 22, 2021
Opinion | Tocilizumab in COVID-19 therapy: who benefits, and how? – the researchers suggest that maybe IL-6 inhibitors should be given only to patients with high IL-6.
23 Jul, 2021 | 10:51h | UTCTocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet
Related: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. AND M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”. AND RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes AND Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less. AND M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.
Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients.
23 Jul, 2021 | 10:47h | UTC
Review: Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit.
23 Jul, 2021 | 10:30h | UTC
Review: Ethics in extracorporeal life support.
23 Jul, 2021 | 10:29h | UTCEthics in extracorporeal life support: a narrative review – Critical Care
Review: The routes of administration for acute postoperative pain medication.
22 Jul, 2021 | 10:46h | UTCThe Routes of Administration for Acute Postoperative Pain Medication – Pain and Therapy
Review: Personalized mechanical ventilation in acute respiratory distress syndrome.
22 Jul, 2021 | 10:40h | UTCPersonalized mechanical ventilation in acute respiratory distress syndrome – Critical Care
Related: M-A of randomized trials: In patients with acute respiratory distress syndrome, there was no difference in mortality between higher vs. lower positive end-expiratory pressure strategies. AND Seminar | Acute respiratory distress syndrome. AND Short review: Diagnosis and management of acute respiratory distress syndrome
RCT: Immediate oral refeeding in patients with mild and moderate acute pancreatitis.
22 Jul, 2021 | 10:32h | UTCImmediate Oral Refeeding in Patients With Mild and Moderate Acute Pancreatitis: A Multicenter, Randomized Controlled Trial (PADI trial) – Annals of Surgery (link to abstract – $ for full-text)
A Narrative Review on the Role of Staphylococcus aureus Bacteriuria in S. aureus Bacteremia.
22 Jul, 2021 | 10:37h | UTC
Commentary on Twitter
✨If you have Staph in urine check blood culture✨
💥Excellent narrative review on the role of Staphylococcus aureus Bacteriuria in S. aureus Bacteremia
Epidemiology and pathogenesis of SABU in patients with SAB💥 #IDTwitter #ofid https://t.co/wioI3I528z pic.twitter.com/54jVQEBeDW— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) March 30, 2021
Expert review | Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy.
21 Jul, 2021 | 10:37h | UTC
Commentary on Twitter
AJOG Expert Review in Preeclampsia: Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy https://t.co/xdZbn51ymU pic.twitter.com/N90GdbdBBw
— AJOG (@AJOG_thegray) July 20, 2021
Cohort study: Sickle cell disorders and severe COVID-19 outcomes – “Our analysis estimated a 4-fold increased risk for COVID-19–related hospitalization and a 2.6-fold increased risk for COVID-19–related death for sickle cell disease”.
21 Jul, 2021 | 10:44h | UTCSickle Cell Disorders and Severe COVID-19 Outcomes: A Cohort Study – Annals of Internal Medicine
ICU Survivorship—The relationship of delirium, sedation, dementia, and acquired weakness.
21 Jul, 2021 | 10:32h | UTC
WHO Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19).
20 Jul, 2021 | 10:29h | UTCRelated Guidance: AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.” AND ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia
International Registry: Ischemic and hemorrhagic stroke among critically ill patients with Covid-19.
20 Jul, 2021 | 10:21h | UTCRelated: SARS-CoV-2 and Stroke Characteristics – higher rate of large vessel occlusions and stroke in young patients AND Case series of 18 male adults aged 50 years or younger with acute ischemic stroke during the convalescent phase of asymptomatic Covid-19 AND Case-control study: COVID-19-associated stroke is associated with worse outcomes and increased mortality AND Pictorial essay: Neurological emergencies associated with COVID-19: stroke and beyond AND Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke AND Risk of Ischemic Stroke in Patients with COVID-19 vs. Patients with Influenza
WHO warns that HIV infection increases risk of severe and critical COVID-19.
20 Jul, 2021 | 10:24h | UTCNews release: WHO warns that HIV infection increases risk of severe and critical COVID-19 – World Health Organization
Commentary on Twitter (thread – click for more)
🆕 report confirms that #HIV infection is a significant independent risk factor for both severe/critical #COVID19 presentation at hospital admission & in-hospital mortality. 23.1% of all people living with HIV who were hospitalized with COVID-19, died.
👉 https://t.co/UBd0OyFKnd pic.twitter.com/UHLo9RPa1g
— World Health Organization (WHO) (@WHO) July 16, 2021